CO6592015A2 - Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal - Google Patents
Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritonealInfo
- Publication number
- CO6592015A2 CO6592015A2 CO12212905A CO12212905A CO6592015A2 CO 6592015 A2 CO6592015 A2 CO 6592015A2 CO 12212905 A CO12212905 A CO 12212905A CO 12212905 A CO12212905 A CO 12212905A CO 6592015 A2 CO6592015 A2 CO 6592015A2
- Authority
- CO
- Colombia
- Prior art keywords
- peritoneal dialysis
- reduce
- compositions
- methods
- cladification
- Prior art date
Links
- 238000000502 dialysis Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002792 vascular Effects 0.000 title 1
- 239000000385 dialysis solution Substances 0.000 abstract 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 2
- 235000011180 diphosphates Nutrition 0.000 abstract 2
- 208000004434 Calcinosis Diseases 0.000 abstract 1
- 230000002308 calcification Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Abstract
Se proporcionan métodos y composiciones para reducir, prevenir o reducir la progresión de la calcificación en pacientes con diálisis peritoneal. En una realización, la presente descripción proporciona un método que comprende administrar a un paciente durante la terapia de diálisis peritoneal una solución de diálisis que comprende una cantidad terapéuticamente eficaz de pirofosfato que oscila entre alrededor de 30 pM y aproximadamente 400 pM. Las formulaciones de soluciones de diálisis de acuerdo con los rangos de dosis reivindicados en la presente descripción permiten que cantidades terapéuticas de pirofosfato sean suministradas apacientes en diálisis peritoneal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32742910P | 2010-04-23 | 2010-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6592015A2 true CO6592015A2 (es) | 2013-01-02 |
Family
ID=44487015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12212905A CO6592015A2 (es) | 2010-04-23 | 2012-11-23 | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110262555A1 (es) |
| EP (1) | EP2560663B1 (es) |
| JP (2) | JP6104155B2 (es) |
| KR (2) | KR20130093471A (es) |
| CN (2) | CN107080752B (es) |
| AU (1) | AU2011242542B2 (es) |
| BR (1) | BR112012027092A2 (es) |
| CA (1) | CA2797138C (es) |
| CO (1) | CO6592015A2 (es) |
| ES (1) | ES2592938T3 (es) |
| MX (1) | MX2012012362A (es) |
| SG (1) | SG184933A1 (es) |
| WO (1) | WO2011133855A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| EP3524288B1 (en) | 2011-03-23 | 2024-11-06 | NxStage Medical Inc. | Peritoneal dialysis systems |
| BR112017014467A2 (pt) * | 2015-01-30 | 2018-01-16 | Fresenius Kabi Deutschland Gmbh | uso de uma mistura de polímeros modificados de glicose para reduzir a metástase tumoral |
| WO2017100621A1 (en) | 2015-12-11 | 2017-06-15 | Nxstage Medical, Inc. | Fluid line connector devices methods and systems |
| CN107550928A (zh) * | 2016-06-30 | 2018-01-09 | 华仁药业股份有限公司 | 一种葡萄糖聚合物腹膜透析液及其制备工艺 |
| EP3512530B1 (en) | 2016-09-15 | 2020-11-18 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Oral pyrophosphate for use in reducing tissue calcification |
| CN111432857A (zh) * | 2017-05-05 | 2020-07-17 | 费森尤斯医疗护理德国有限责任公司 | 腹膜透析浓缩物、腹膜透析袋和用于连续非卧床腹膜透析或自动腹膜透析的套件 |
| US12048791B2 (en) | 2017-06-24 | 2024-07-30 | Nxstage Medical, Inc. | Peritoneal dialysis fluid preparation and/or treatment devices methods and systems |
| US11207454B2 (en) | 2018-02-28 | 2021-12-28 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
| MX2021003191A (es) | 2018-09-26 | 2021-05-27 | Nxstage Medical Inc | Dispositivos y metodos de sellado de canales de fluido configurables. |
| JP2022540664A (ja) * | 2019-07-12 | 2022-09-16 | スティヒティング・ヘット・ネーデルランズ・カンカー・インスティテュート－アントニ・ファン・レーウェンフック・ゼィークンホイス | 石灰化減少に用いる経口ピロリン酸二ナトリウム |
| CN113304132A (zh) * | 2021-06-11 | 2021-08-27 | 北京畅盛医药科技有限公司 | 一种治疗肾透析患者心脑血管疾病专用的透析液 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998028569A1 (fr) * | 1996-12-20 | 1998-07-02 | Kikkoman Corporation | Outil luminescent, son element auxiliaire et procede de conservation de la composition bioluminescente utilisee dans l'outil et l'element auxiliaire |
| EA002479B1 (ru) * | 1996-12-31 | 2002-06-27 | Аджай Гупта | Способ и фармацевтическая композиция для доставки железа у пациентов, получающих гемодиализ и перитонеальный диализ |
| US6309673B1 (en) | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
| JP3672036B2 (ja) * | 2002-03-19 | 2005-07-13 | 松下電器産業株式会社 | 無機リン酸、ピロリン酸及び核酸の検出方法並びにｄｎａのｓｎｐ配列をタイピングする方法 |
| AU2004287440A1 (en) * | 2003-10-28 | 2005-05-19 | Emory University | Dialysates and methods and systems related thereto |
| US8187467B2 (en) * | 2003-12-30 | 2012-05-29 | Ajay Gupta | Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion |
| US7658952B2 (en) * | 2007-10-11 | 2010-02-09 | Baxter International Inc. | Dialysis solutions containing pyrophosphates |
-
2011
- 2011-04-22 AU AU2011242542A patent/AU2011242542B2/en not_active Ceased
- 2011-04-22 KR KR1020127028250A patent/KR20130093471A/ko active Application Filing
- 2011-04-22 KR KR1020177022907A patent/KR102080749B1/ko active Active
- 2011-04-22 EP EP11717157.9A patent/EP2560663B1/en active Active
- 2011-04-22 US US13/092,324 patent/US20110262555A1/en not_active Abandoned
- 2011-04-22 SG SG2012077533A patent/SG184933A1/en unknown
- 2011-04-22 BR BR112012027092A patent/BR112012027092A2/pt not_active IP Right Cessation
- 2011-04-22 CN CN201610878521.6A patent/CN107080752B/zh active Active
- 2011-04-22 MX MX2012012362A patent/MX2012012362A/es active IP Right Grant
- 2011-04-22 ES ES11717157.9T patent/ES2592938T3/es active Active
- 2011-04-22 JP JP2013506322A patent/JP6104155B2/ja active Active
- 2011-04-22 CA CA2797138A patent/CA2797138C/en active Active
- 2011-04-22 CN CN2011800205059A patent/CN102858351A/zh active Pending
- 2011-04-22 WO PCT/US2011/033571 patent/WO2011133855A1/en active Application Filing
-
2012
- 2012-11-23 CO CO12212905A patent/CO6592015A2/es not_active Application Discontinuation
-
2014
- 2014-10-30 US US14/528,222 patent/US20150093450A1/en not_active Abandoned
-
2015
- 2015-10-30 JP JP2015213826A patent/JP2016020394A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130093471A (ko) | 2013-08-22 |
| CN107080752B (zh) | 2020-07-31 |
| BR112012027092A2 (pt) | 2016-07-26 |
| ES2592938T3 (es) | 2016-12-02 |
| SG184933A1 (en) | 2012-11-29 |
| CN107080752A (zh) | 2017-08-22 |
| EP2560663B1 (en) | 2016-06-22 |
| MX2012012362A (es) | 2012-11-30 |
| JP2016020394A (ja) | 2016-02-04 |
| EP2560663A1 (en) | 2013-02-27 |
| US20110262555A1 (en) | 2011-10-27 |
| JP6104155B2 (ja) | 2017-03-29 |
| AU2011242542B2 (en) | 2014-11-27 |
| CA2797138A1 (en) | 2011-10-27 |
| KR102080749B1 (ko) | 2020-02-24 |
| KR20170098321A (ko) | 2017-08-29 |
| US20150093450A1 (en) | 2015-04-02 |
| AU2011242542A1 (en) | 2012-11-08 |
| WO2011133855A1 (en) | 2011-10-27 |
| CA2797138C (en) | 2018-10-02 |
| JP2013525374A (ja) | 2013-06-20 |
| CN102858351A (zh) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6592015A2 (es) | Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2022004012A (es) | Solucion de bloqueo de cateter y terapia de bloqueo de cateter. | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| MX2014004548A (es) | Metodos para tratar pacientes pediatricos usando dexmedetomidina. | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| PH12015500407B1 (en) | Methods of treating hypertriglyceridemia | |
| MX354702B (es) | Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral. | |
| MX2015013355A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| WO2012023623A3 (ja) | ハンター症候群の治療剤 | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
| ZA202209104B (en) | Intradialytic use of sodium thiosulfate | |
| ZA202307367B (en) | Intradialytic use of sodium nitrite | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| MX2015014939A (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| RU2010129491A (ru) | Способ лечения и профилактики кариеса зубов | |
| RU2012155369A (ru) | Способ лечения язвенного пилородуоденального стеноза | |
| GT201700041A (es) | Tratamientos médicos a base de anamorelina | |
| NZ740627A (en) | Oral suspension for treating eosinophilic esophagitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |